Pharmaceutical Industry 22 January 2026

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

The Cigna Group’s shares jumped about 3.2% to $280.46 in late morning trading Thursday after it unveiled quarterly results and its 2026 outlook. UnitedHealth slipped nearly 1.6%, CVS Health rose close to 2.2%, and Elevance slipped around 0.7%. CI stock traded in a range from $270.00 up to $283.59.

5 February 2026

Earnings Reports·NYSE:CI·Pharmaceutical Industry·Stock Market

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares jumped roughly 9% on Wednesday, closing near $1,096 after hitting an intraday peak of $1,110.98. This gain stood out as the broader market slipped, with the SPY falling about 0.3% and the QQQ dropping close to 1.5%.

4 February 2026

Earnings Reports·NYSE:LLY·Pharmaceutical Industry·Stock Market

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer Inc shares climbed roughly 3.7% to $26.73 by early Wednesday afternoon, bouncing back after a roughly 3.3% drop the previous day.

4 February 2026

NYSE:PFE·Pharmaceutical Industry·Stock Market

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics, the biopharma working on an oral hair-loss treatment, set its IPO price at $17 a share, above the initial range, pulling in roughly $256.3 million. The stock is slated to start trading Wednesday on the New York Stock Exchange under the ticker “MANE.”

4 February 2026

Biotechnology·NYSE:MANE·Pharmaceutical Industry·Stock Market

Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich Insurance Group has struck outline terms for an about 8 billion pound cash takeover of FTSE 100 underwriter Beazley, with Beazley saying it would be minded to recommend the offer if Zurich turns it into a firm bid by Feb. 16.

4 February 2026

Artificial Intelligence·FTSE 100·LSE:BEZ·Pharmaceutical Industry·Stock Market·SWX:ZURN.SW

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares climbed Tuesday afternoon, despite cautious trading ahead of the drugmaker’s quarterly earnings report set for Wednesday before the U.S. open. By 3:46 p.m. ET, the stock gained $1.91, roughly 0.8%, to $227.55, after hitting an intraday high of $228.66.

3 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceutical Industry·Stock Market

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Johnson & Johnson shares climbed roughly 1.4% Tuesday following an initial drop, boosted by the company’s newest update on its heart device. The stock traded at $233.87 in the afternoon, bouncing between $230.00 and $235.24 earlier in the session.

3 February 2026

NYSE:JNJ·Pharmaceutical Industry

Novo Nordisk stock slides as broker cuts rating ahead of Feb. 4 earnings

Novo Nordisk shares dipped Monday following a broker downgrade just before this week’s earnings, adding to the Danish drugmaker’s stock pressure in early February trading.

2 February 2026

CSE:NOVO-B.CO·Earnings Reports·Pharmaceutical Industry·Stock Market

Merck stock price ends higher ahead of Feb. 3 earnings — what MRK investors watch next week

Merck shares climbed 1.8% on Friday, finishing at $110.27. Investors are bracing for this week’s update on sales and earnings from the drugmaker.

1 February 2026

Earnings Reports·NYSE:MRK·Pharmaceutical Industry·Stock Market

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares ended Friday roughly 6% higher, closing at $6.25. That stands out as the S&P 500 tracker SPY dipped around 0.4%, and the Nasdaq 100 tracker QQQ dropped about 1.2%. The stock fluctuated between $5.68 and $6.45, with trading volume hitting close to 29.5 million shares.

1 February 2026

NASDAQ:IBRX·Pharmaceutical Industry·Stock Market

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck & Company, Inc. shares closed Friday on an uptick, outperforming a weaker U.S. market and holding close to a recent high.

31 January 2026

Earnings Reports·NYSE:MRK·Pharmaceutical Industry·Stock Market

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

• Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.

29 January 2026

Biotechnology·NASDAQ:DNLI·NASDAQ:RGNX·Pharmaceutical Industry·Stock Market

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Shares of Gilead Sciences climbed $2.46, or 1.8%, to $140.24 Tuesday afternoon, hitting a fresh 12-month peak at $141.69 earlier in the session.

27 January 2026

Earnings Reports·NASDAQ:GILD·Pharmaceutical Industry·Stock Market

AbbVie stock rises as insurers crater and the Fed week kicks off

AbbVie Inc. shares climbed roughly 1.5% to $224.12 in Tuesday afternoon trading, having peaked earlier at $226.83. Johnson & Johnson also rose about 1.5%, and Pfizer was up around 2.6%. Meanwhile, Eli Lilly fell close to 1.2%.

27 January 2026

NYSE:ABBV·Pharmaceutical Industry

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie Inc. shares edged up roughly 0.4% to hit $220.10 in afternoon trading on Monday, fluctuating between $217.15 and $221.48 earlier in the session.

26 January 2026

Earnings Reports·NYSE:ABBV·Pharmaceutical Industry·Stock Market

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.

26 January 2026

Healthcare News·LSE:GSK·Pharmaceutical Industry

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares climbed 3.65%, closing at $135.93 on Friday. The stock gained momentum after fresh breast cancer data refocused attention on the company’s oncology efforts.

24 January 2026

NASDAQ:GILD·Pharmaceutical Industry

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly and Company shares gained roughly 0.8% in after-hours Thursday, last seen at $1,087.38, up $8.81. During the session, the stock fluctuated between $1,072.46 and $1,095.15.

23 January 2026

Earnings Reports·NYSE:LLY·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson shares ended Thursday roughly 0.3% higher at $218.49, after moving between $217 and $221.86 during the session. Trading volume hit around 13 million shares.

22 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson shares dipped 0.05% to $218.01 in after-hours trading Wednesday, swinging from a low of $209.20 to a high of $218.61. Investors balanced the company’s 2026 forecast with fresh scrutiny over talc-related lawsuits.

22 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Pharmaceutical Industry 22 January 2026 - 5 February 2026